Johns Hopkins interferon inducer Ampligen
FDA recently gave go-ahead to shipment of Ampligen for Far East hepatitis/hepatoma clinicals. U.S. Phase II cancer trials are currently underway at Hahnemann University in Philadelphia ("The Pink Sheet" May 21, T&G-3), and more recently at M.D. Anderson in Houston
You may also be interested in...
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.
Sensyne obtained UK regulatory approval for its SYNE-COV machine learning algorithm to assess the long-term risks of COVID-19.
While the EU attempts to accelerate the pace of its unified approach to vaccine roll-out, some eastern European countries are taking their own decisions.